LLY Trading Analysis - 10/27/2026 04:40 PM — TRU-SENTIMENT

News Headlines & Context

The following items reflect general knowledge context only and are separated from the data-driven analysis below:

• Eli Lilly (LLY) reported strong Q3 2026 momentum in tirzepatide and obesity franchise, with continued global supply expansion cited in industry coverage.
• Recent FDA label expansions for GLP-1 therapies have kept LLY in focus as a sector leader in metabolic drugs.
• Management highlighted manufacturing scale-up plans through late 2026 to address backlog demand.
• Broader pharma sector saw defensive rotation amid macro uncertainty, with low-beta names like LLY favored.
• No specific near-term earnings date was confirmed in provided data; daily history shows elevated volume around mid-October rallies.

Context: Headlines around obesity-drug leadership and supply expansion align with the bullish options flow and strong daily uptrend seen in the embedded data, though news is not part of the quantitative read below.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS JSON:

• Trailing P/E: 42.50; Trailing EPS: $29.96; Market Cap: $1,142,639,451,870.00
• Dividend Yield: 0.54% (Rate $6.92); Ex-Dividend: 2026-08-14
• Beta: 0.46 (low volatility vs market); 52-Week High: $1,321.21; 52-Week Low: $809.63
• Institutional Ownership: 55.51%; Shares Outstanding: 891,357,000
• Historical Volatility: 26.79%; Average Volume: 2,324,000
• PEG Ratio, Forward P/E, Forward EPS, Profit Margins, ROE, Debt/Equity, Free Cash Flow, Revenue Growth, Total Revenue: null/not provided
• Analyst Consensus / Target Mean Price: null (no provided target or recommendation key)

Fundamental strengths: low beta and large-cap defensiveness. Concerns: rich trailing P/E of 42.50 with no margin or growth data to justify. Fundamentals show stability but cannot confirm the strong technical uptrend; technicals are leading fundamentals in this dataset.

Current Market Position

Current price (2026-10-27 close): $1,282.17. Recent daily action shows a rally from $1,131.21 (2026-10-08 low) to $1,321.21 (2026-10-22 high) then consolidation: 2026-10-26 close $1,279.06, 2026-10-27 close $1,282.17 on volume 1,216,955 (below 20-day avg 1,598,916).

Minute bars (2026-10-26 to 2026-10-27 15:55): Open 1,286.39 → low 1,273.73 → recovered to 1,283.83 last bar. Late-session bounce from 1,278.01 (15:35) to 1,283.83 shows mild intraday momentum improvement.

Technical Analysis

SMA alignment: Price ($1,282.17) > SMA5 ($1,282.97 ~) > SMA20 ($1,215.96) > SMA50 ($1,191.20): bullish stack, no bearish cross. RSI 66.55 = strong momentum, not yet overbought (>70). MACD hist +6.34 confirms bullish momentum. Bollinger: price inside upper $1,326.64 / mid $1,215.96 = expansion, not squeeze. 30-day range $1,131.21–$1,321.21: price at ~85% percentile.

True Sentiment Analysis (Delta 40-60 Options)

Options flow (2026-10-27 16:40) via Delta 40-60 filter:

Call Dollar Volume: $11,105,105.00 (61.5%) Put Dollar Volume: $6,941,045.00 (38.5%) Total: $18,046,150.00

Sentiment: Bullish. 1,664 call contracts vs 1,042 put; 124 call trades vs 91 put. Pure directional conviction leans bullish into 2026-11-20. No divergence vs technicals (both bullish).

Key Price Levels (Observational Only)